Clinical trials in the Asia Pacific are increasing exponentially. Numerous sponsors and CROs have accessed this region in recent years to take advantage of high performing, cost effective sites. To many sponsors though, Asia Pacific appears an impenetrable black box. To successfully tap into it means navigating regulatory and operational challenges compounded by language and cultural barriers.
